In vitro evaluation of CAR-T cells in patient-derived glioblastoma models

Advances in chimeric antigen receptor (CAR) T cell therapies have led to the modality dominating translational cancer research; however, a standardized protocol for evaluating such therapies in vitro is needed. This protocol details the in vitro preclinical evaluation of CAR-T cell therapies for gli...

Descripción completa

Detalles Bibliográficos
Autores principales: Brakel, Benjamin A., Chokshi, Chirayu R., Salim, Sabra K., Venugopal, Chitra, Singh, Sheila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567433/
https://www.ncbi.nlm.nih.gov/pubmed/34761232
http://dx.doi.org/10.1016/j.xpro.2021.100920
Descripción
Sumario:Advances in chimeric antigen receptor (CAR) T cell therapies have led to the modality dominating translational cancer research; however, a standardized protocol for evaluating such therapies in vitro is needed. This protocol details the in vitro preclinical evaluation of CAR-T cell therapies for glioblastoma (GBM), including target cell cytotoxicity and T cell proliferation, activation, and cytokine release assays. For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).

Ejemplares similares